Gene delivery systems for use in gene therapy: An overview of quality assurance and safety issues

Gene Therapy

Volumn 3, Issue 3, 1996, Pages 190-200

  Smith, K T ^a   Shepherd, A J ^a   Boyd, J E ^a   Lees, G M ^a  

^a Q One Biotech Ltd   (United Kingdom)

Author keywords

GNP production; Regulatory issues; Validation

Indexed keywords

ADENOVIRUS; DNA TRANSFECTION; EXPRESSION VECTOR; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; GOOD LABORATORY PRACTICE; GOOD MANUFACTURING PRACTICE; HERPES VIRUS; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; RETROVIRUS; REVIEW; RISK ASSESSMENT; VIRUS; VIRUS RECOMBINANT;

GENE THERAPY; GENETIC VECTORS; HUMANS; QUALITY ASSURANCE, HEALTH CARE; VIRAL PHYSIOLOGY; VIRUS REPLICATION; VIRUSES;

EID: 0029944718     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Anderson WF. Human gene therapy. Science 1992; 256: 808-813.
2. Arrand J, Lees GM. Gene therapy: an overview of adenovirus vectors. Technical Bulletin no. 18. Q-One Biotech Ltd, Glasgow, 1994.
3. Gloriosco JC, Goins WF, Fink DJ. Herpes simplex virus-based vectors. Semin Virol 1992; 3: 265-276.
4. Grunhaus A, Horwitz MS. Adenoviruses as cloning vectors. Semin Virol 1992; 3: 237-252.
5. Onions D, Lees G. The use of retroviral vectors in gene therapy. Technical Bulletin no. 17. Q-One Biotech Ltd, Glasgow, 1993.
6. Wolff JA et al. Direct gene transfer into mouse muscle in vivo. Science 1990; 247: 1465-1468.
7. Cotten M et al. Transferrin-polycation-mediated introduction of DNA into human leukemic cells: stimulation by agents that affect the survival of transfected DNA or modulate transferrin receptor levels. Proc Natl Acad Sci USA 1990; 87: 4033-4037.
8. Kitsis RN et al. Hormonal modulation of a gene injected into rat heart in vivo. Proc Natl Acad Sci USA 1991; 88: 4138-1142.
9. Bakrinsky MI et al. A nuclear localization signal within HIV-1 matrix protein that governs infection of non-dividing cells. Nature 1993; 365: 666-669.
10. Moss B et al. New mammalian expression vectors. Nature 1990; 348: 91-92.
11. Porter DC, Ansardi DC, Choi WS, Morrow CD. Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 gag and pol proteins upon infection. J Virol 1993; 67: 3712-3719.
12. Bredenbeek PJ, Frolov I, Rice CM, Schesinger S. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol 1993; 67: 6439-6446.
13. Bredenbeek PJ, Rice CM. Animal RNA virus expression systems. Semin Virol 1992; 3: 297-310
14. Russel SJ et al. Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J Virol 1992; 66: 2821-2828.
15. Hermonat PL, Muzyczka N. Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 1994; 91: 6466-6470.
16. Stein CA, Cheng Y-C. Antisense oligonucleotides as therapeutic agents - is the bullet really magical. Science 1993; 261: 1004-1012.
17. Buchardt O, Egholm M, Berg RH, Nielsen PE. Peptide nucleic acids and their potential applications in biotechnology. Trends Biotechnol 1993; 11: 384-386.
18. 3/T (90) 18. Products of recombinant DNA technology. Pharmeuropa 1990; 2: 126-128.
19. European Council Directive 90/220/EEC. On the deliberate release into the environment of genetically modified organisms. Official Journal of the European Communities 1990; L117: 15-27.
20. NIH Guidelines for Research Involving Recombinant DNA Molecules. 1984; 49 Federal Register 46266. Section III-A-G.
21. Gene Therapy Advisory Committee. Guidance on making proposals to conduct gene therapy research on human subjects. 1994; Department of Health, London, UK.
22. Williamson JD et al. Biological characterization of recombinant vaccinia viruses in mice infected by the respiratory route. J Gen Virol 1990; 71: 2761-2767.
23. Advisory Committee on Dangerous Pathogens and Advisory Committee on Genetic Modification. Vaccination of laboratory workers handling vaccinia and related poxviruses infectious for humans. HMSO, London, 1990.
24. Lane JM, Ruben FL, Neff JM, Miller JD. Complications of small-pox vaccination, 1968. National surveillance in the United States. New Engl J Med 1969; 281: 1201-1208.
25. Tartaglia J, Perkus ME, Taylor J et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 1992; 188: 217-232.
26. Medicines Control Agency Rules and guidance for pharmaceutical manufacturers. HMSO, London, 1993.
27. Department of Health. Good laboratory practice: the United Kingdom compliance programme. Department of Health, London, 1989.
28. Centre for Biologics Evaluation and Research (CBER) US. Points to consider in the characterization of cell lines used to produce biologicals, 1993.
29. Committee for Proprietary Medicinal Products. Ad hoc working party on biotechnology/pharmacy and working party on safety of medicines. Notes to applicants for marketing authorizations on the pre-clinical biological safety testing of medicinal products derived from biotechnology (and comparable products derived from chemical synthesis). J Biol Stand 1989; 17: 203-212.
30. Committee for Proprietary Medicinal Products. Ad hoc working party on biotechnology/pharmacy. Notes to applicants for marketing authorizations on the production and quality control of monoclonal antibodies of murine origin intended for use in man. J Biol Stand 1989; 17: 213-222.
31. Committee for Proprietary Medicinal Products. Ad hoc working party on biotechnology/pharmacy. Notes to applicants for marketing authorizations on the production and quality control of medicinal products derived by recombinant DNA technology. J Biol Stand 1989; 17: 223-231.
32. Centre for Biologics Evaluation and Research (CBER) US. Points to consider in the human somatic cell therapy and gene therapy. 1991.
33. US DoHSS. NIH points to consider in the design and submission of protocols for the transfer of recombinant DNA into the genome of human subjects. Notice Fed Reg 1990; 55: 744-748.
34. Epstein SL. Regulatory concerns in human gene therapy. Hum Gen Ther 1991; 2: 243-249.
35. Chen TR. Re-evaluation of HeLa, HeLa S3 and HEp-2 karyotypes. Cytogenet Cell Genet 1988; 48: 19-24.
36. Gilbert DA et al. Application of DNA fingerprints for cell line individualization. Am J Hum Gen 1990; 47: 499-514.
37. Smith KT, Lees G. Viral gene delivery systems for use in gene therapy: an overview of quality assurance and safety issues. Technical Bulletin no. 16. Q-One Biotech Ltd, Glasgow, 1994.
38. Centre for Biologics and Research (CBER) US. Supplement to the points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA Technology: nucleic acid characterization and genetic stability. 1992, and Supplement.
39. Bett AJ, Prevec L, Graham FL. Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 1993; 67: 5911-5921.
40. Holland JJ. Defective viral genomes. In: Fields BN, et al (eds). Virology (2nd edn). Raven Press: New York, 1990, pp 151-165.
41. Imperiale M-J et al. Common control of the heat shock gene and early adenovirus genes: evidence for a cellular E1a-like activity. Mol Cell Biol 1984; 4: 867-874.
42. Spergel JM et al. NF-IL6, a member of the C/EBP family, regulates E1a-responsive promoters in absence of E1a. J Virol 1992; 66: 1021-1030.
43. Horvath J, Faxing C, Weber J. Complementation of adenovirus early region 1a and 2a mutants by Epstein-Barr virus-immortalized cell lines. Virology 1991; 184: 141-148.
44. Horvath J, Palkonyay L, Weber J. Group C adenovirus sequences in human lymphoid cells. J Virol 1986; 59: 189-192.
45. Cornetta K et al. Amphotropic murine leukaemia retrovirus is not an acute pathogen for primates. Hum Gen Ther 1990; 1: 15-30.
46. Donahue RE et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992; 176: 1125-1135.
47. Otto E et al. Characterization of a replication-competent retrovirus resulting from recombination of packaging and vectorell line that lacks sequences closely related to endogenous murine leukaemia viruses and sequences. Hum Gen Ther 1994; 5: 567-575.
48. Lander MR, Chattopadhyay SK. A Mus dunni cell line that lacks sequences closely related to endogenous murine leukaemia viruses and can be infected by ecotropic, amphotropic, xenotropic and mink cell focus-forming viruses. J Virol 1984; 52: 695-698.
49. Printz M et al. Recombinant retroviral vector interferes with the detection of amphotropic replication competent retrovirus in standard culture assays. Gene Therapy 1995; 2: 143-150.
50. Yuhasz SA, Stevens JG. Glycoprotein B is a specific determinant of herpes simplex virus type 1 neuroinvasiveness. J Virol 1993; 67: 5948-5954.
51. Birmanns B, Reibstein I, Steiner I. Characterization of an in vivo reactivation model of herpes simplex virus from mice trigeminal ganglia. J Gen Virol 1993; 74: 2487-2491.
52. Steiner I et al. A herpes simplex virus type 1 mutant containing a non-transinducing Vmw65 protein establishes latent infection in vivo in the absence of viral replication and reactivates efficiently from explanted trigeminal ganglia. J Virol 1990; 64: 1630-1638.